ASCO 2019 day four
Exclusive live coverage from day four of the American Society of Clinical Oncology’s annual meeting in Chicago.
• To view all of our coverage from the preeminent cancer event, produced in association with Kantar Health, as well as additional content, visit the Spotlight on ASCO 2019 and the future of oncology
Key highlights for Monday:
- Seattle Genetics will present details of EV-201, also known as enfortumab vedotin monotherapy in locally advanced metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
- Bayer will present additional data on its larotrectinib in TRK fusion cancers, a precision medicine that works on cancers of any origin in the body that are driven by the mutation driven by tropomyosin receptor kinase (TRK).
- Another highlight is an oral presentation of the first phase 2 data from the CaboGIST study (trial 1317) from the European Organization for Research and Treatment of Cancer (EORTC), investigating the activity and safety of Ipsen/Exelixis’ cabozantinib in patients with metastatic gastrointestinal stromal tumour after failure of imatinib and sunitinib.
View the live coverage from day four at ASCO 2019 below (the live blog may take a few seconds to load) and we will also have live coverage from day five at ASCO: